Atrial Fibrillation Treatment Market Size to Reach USD 37.42 Bn by 2033

The atrial fibrillation treatment market size was valued at USD 23.06 billion in 2023 and is expected to reach around USD 37.42 billion by 2033, growing at a CAGR of 5.2% from 2024 to 2033.

Ottawa, March 21, 2024 (GLOBE NEWSWIRE) — The global atrial fibrillation treatment market size is calculated at USD 23.72 billion in 2024 and is projected to surpass around USD 34.68 billion by 2032, a study published by Towards Healthcare a sister firm of Precedence Research.

Insight Highlights:

  • Catheter ablation leads the charge, holding a dominant 54% market share in 2023 and showcasing its effectiveness in controlling irregular heartbeats.
  • Catheter ablation is also set to be the fastest-growing segment, further solidifying its dominance in the AFib market.

The National Institute of Health says atrial fibrillation is on the rise globally, especially with age. They predict that by 2050, the number of people with this condition could double or triple. This highlights the urgent need for better treatment options as the prevalence increases.

Heart and blood vessel diseases, known as cardiovascular diseases (CVDs), are increasingly prevalent, causing around 17.9 million deaths globally each year. These conditions encompass heart attacks, strokes, atrial fibrillation, and others. Heart attacks and strokes make up over 80% of CVD deaths, with one-third happening before age 70.

Download a short version of this report @ https://www.towardshealthcare.com/personalized-scope/5120

For instance,

  • In 2021, the World Heart Federation estimates that heart diseases, also known as cardiovascular diseases (CVDs), are still the main reason why people die worldwide, causing around 20.5 million deaths in the year 2021.
  • In 2021, the United States saw the highest number of heart transplants ever, with 3,817 performed. California, Texas, New York, and Florida had the most heart transplant surgeries, with California leading at 529, followed by Texas with 359, New York with 307, and Florida with 263.

Atrial fibrillation is a common problem with the heart’s rhythm. It happens when the upper chambers of the heart don’t beat regularly. Instead, they quiver or shake. This can make it hard for the heart to pump blood properly and can raise the chance of blood clots forming in the heart. A few things can cause atrial fibrillation, like having high blood pressure, heart disease, being overweight, having sleep problems like sleep apnea, or drinking too much alcohol. Doctors usually find atrial fibrillation by doing a test called an electrocardiogram (ECG), which checks for irregular heartbeats. It’s super important to catch atrial fibrillation early because it can lead to severe problems like strokes, heart failure, and other heart issues. Treating atrial fibrillation quickly with medications like blood thinners to stop clots from forming or procedures like catheter ablation to fix the heart’s rhythm can really help manage atrial fibrillation and lower the risks. The market for treating atrial fibrillation has been growing a lot because more people are becoming aware of it, technology in medicine is getting better, and there are more risk factors like getting older and changing lifestyle habits. So, scientists are constantly working on new ways to help people with atrial fibrillation have better outcomes.

Increased Incidence of Atrial Fibrillation

As people get older, they’re more likely to develop atrial fibrillation because of aging and other risk factors that build up over time. With the global population aging, more and more people are being diagnosed with atrial fibrillation. This creates a big challenge for healthcare systems everywhere because it means they have to provide effective treatments for atrial fibrillation.

Atrial fibrillation is the most commonly encountered irregular heartbeat condition within the heart. Its prevalence has been on a steady rise globally. Typically, the likelihood of experiencing atrial fibrillation increases with age, with estimations suggesting a doubling or even tripling of affected individuals by the year 2050. While the worldwide occurrence of atrial fibrillation hovers around 1%, it notably spikes to about 9% among those aged 75 and older. Additionally, upon reaching 80 years of age, the risk of developing atrial fibrillation over a lifetime surges to 22%. Furthermore, research indicates that atrial fibrillation is more frequently observed in males and is more prevalent among individuals of white ethnicity compared to those of black ethnicity.

So, there’s a greater need for doctors and hospitals to give good care to atrial fibrillation patients, which includes giving them medicines and doing procedures to fix their irregular heartbeats and prevent problems like blood clots and strokes. Because atrial fibrillation is becoming more common, developing new and better ways to treat it is essential. That’s why much research is going on to understand atrial fibrillation better and find treatments that work well. Doctors, scientists, government officials, and groups supporting patients are all working together to tackle the many challenges of atrial fibrillation. Moreover, it’s crucial to focus on preventing atrial fibrillation and catching it early to avoid complications and reduce the pressure on healthcare systems. Because atrial fibrillation is becoming more widespread, it’s prompting us to invest more in research, healthcare facilities, and education to improve care and outcomes for people with this heart condition.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Medical Technology Advances Have Led to New Devices Aiding Atrial Fibrillation Treatment

Advanced technology Scientists worldwide are focused on understanding atrial fibrillation and developing better treatment methods. This research is super important because it helps us figure out why atrial fibrillation happens and how to improve it. They’re developing new treatments, like medicines, special devices, and procedures, to help people with atrial fibrillation feel better and live longer. These treatments aim to fix the problems in the heart’s electrical system that cause atrial fibrillation and reduce the chances of severe issues like strokes.

Improvements in technology are changing how healthcare works, especially for heart problems. With more people having heart issues, there’s a growing need for better tools to diagnose and treat them faster. Big companies are coming up with new ways to treat atrial fibrillation.

Additionally, significant improvements in medical technology have led to new devices that can help regulate the heart’s rhythm or prevent blood clots in people with atrial fibrillation. These new tools are up-and-coming and could improve life for atrial fibrillation patients. Scientists are also looking into how lifestyle changes, like eating healthier and exercising, can help manage atrial fibrillation and make living easier.

Newer Device and Medication for Atrial Fibrillation Treatment Approved by FDA

Device:

  • In October 2023, the Aurora EV-ICD System made by Abbott was approved. This system is for people who have a high risk of sudden heart problems but can’t use regular pacemakers because their heart beats too slowly. It can also find and treat episodes of atrial fibrillation.

Medication Updates:

  • In November 2023, Pembrolizumab, known as Keytruda by Merck, was approved for broader use. It’s an immunotherapy drug used to treat cancer, and now it can also be used as the first treatment for a specific type of stomach or gastroesophageal junction cancer in certain patients who have a particular protein called HER2. Although not specifically for atrial fibrillation, some research shows it might help reduce inflammation associated with worsening atrial fibrillation.

The main goal of all this research is to find better ways to treat atrial fibrillation and improve life for people with the condition. By learning more about atrial fibrillation and trying out new ideas, scientists hope to find treatments that can ease symptoms, prevent serious problems, and improve life for people with atrial fibrillation. It’s a team effort involving scientists, doctors, and groups that support patients, and it’s all about ensuring everyone affected by atrial fibrillation can have a brighter future with better care and treatments.

Customize this study as per your requirement @ https://www.towardshealthcare.com/customization/5120

The Role of Catheter Ablation

Over the past 25 years, there has been a lot of interest in developing new tools and techniques to make ablation treatments for atrial fibrillation safer and more effective. Initially, doctors used catheters with small tips and radiofrequency energy to create tissue lesions in the heart. However, they started using catheters with irrigation and measuring contact force over time to improve accuracy and power. Additionally, they developed single-shot devices like balloons to create more extensive lesions, and they switched to using cryogenic and electrical current for ablation. Thanks to these advancements in ablation techniques, it has become easier to treat atrial fibrillation.

For instance,

  • In December 2023, the FDA approved the PulseSelect Pulse Field Ablation (PFA) system for treating atrial fibrillation. This system is a minimally invasive procedure that uses electrical pulses to destroy problematic heart tissue causing atrial fibrillation.

Catheter ablation techniques have entirely changed how doctors treat atrial fibrillation, providing a less invasive option compared to traditional surgery. With catheters inserted through blood vessels, doctors can precisely target and remove abnormal heart tissue causing atrial fibrillation, which helps restore a normal heart rhythm. This approach means patients don’t need open-heart surgery, so they spend less time in the hospital and recover faster. Catheter ablation has also proven to be more effective than just taking medication for managing atrial fibrillation symptoms and preventing complications like strokes. Because it’s prosperous and safer, more patients and doctors prefer catheter ablation, significantly increasing demand for these procedures.

Furthermore, ongoing improvements in catheter technology and techniques make atrial fibrillation ablation even better and safer. Catheter ablation has become a crucial part of managing atrial fibrillation, giving hope to many people with this common heart problem.

Browse More Insights of Towards Healthcare:

  • The global electronic health records (EHR) market boomed $ 27.42 billion in 2023 and is expected $ 41.87 billion by 2033, growing at a 5.1% of CAGR from 2023 to 2033.
  • The global burn care market size surpassed USD 2.73 billion in 2023 and is set to blaze USD 4.41 billion by 2033, expanding with a 7.1% of CAGR from 2023 to 2033.
  • The U.S. child care market size surpassed USD 59.87 billion in 2023 and is estimated to hit 88.22 billion by 2033, growing at a 4.3% of CAGR from 2023 to 2033.
  • The global legal marijuana market size was valued at $30.75 billion in 2023 and is projected $113.26 billion by 2033, registered a at 14.4% of CAGR from 2023 to 2033.
  • The global sports medicine market size was valued at USD 5.89 billion in 2023 and is to hit USD 10.82 billion by 2033, expanding at a 6.6% of CAGR from 2023 to 2033.
  • The global biologics market size surpassed USD 419.07 billion in 2023 and is projected USD 845.78 billion by 2033, increasing at a 7.6% of CAGR from 2023 to 2033.
  • The global mHealth market size was valued at USD 60.65 billion in 2023 and is to hit USD 176.54 billion by 2033, expanding at a CAGR of 11.6% from 2023 to 2033.
  • The global home healthcare market size was valued at USD 192.4 billion in 2023 and is projected USD 427.69 billion by 2033, increasing at a 8.6% of CAGR from 2023 to 2033.
  • The global corticosteroids market size surpassed USD 4.71 billion in 2023 is projected to hit USD 6.91 billion by 2033, growing at a 4.2% CAGR from 2023 to 2033.
  • The global telehealth and telemedicine market size surpassed $ 214.55 billion in 2023 to reach $ 869.22 billion by 2033, growing at a 15.5% CAGR between 2023 and 2033.

Serious Complications Can Occur if Atrial Fibrillation is Not Diagnosed Early

Even with all the progress made in finding and treating atrial fibrillation, there are still significant problems with not spotting it early enough or not giving the proper treatment. A lot of people who have atrial fibrillation don’t even know they have it, or they don’t get the appropriate treatment for it. This is a big deal because they’re at higher risk of severe problems. If atrial fibrillation is missed and treated early, it can lead to complications like strokes or heart failure. There are a few reasons why this happens. Sometimes, atrial fibrillation doesn’t show any apparent symptoms, so people don’t realize there’s a problem.

Other times, healthcare providers might not think to check for atrial fibrillation, especially if a person doesn’t have any symptoms. This can lead to missed opportunities for diagnosis and treatment. Also, even if atrial fibrillation is diagnosed, not everyone gets the proper treatment. This could be due to various factors like lack of awareness about atrial fibrillation or limited access to healthcare. Addressing these issues is crucial to improving outcomes for people with atrial fibrillation and reducing the risk of complications. This includes raising awareness about atrial fibrillation, improving access to healthcare, and ensuring that healthcare providers are appropriately screening for and treating atrial fibrillation.

Geographical Landscape

North America is expected to be at the forefront of the market because there are more cases of atrial fibrillation there, and many people are affected. Additionally, large companies in the region contribute to this leading position. According to the CDC, it’s predicted that by 2030, around 12.1 million individuals in the United States will have atrial fibrillation. As people get older, there will be an increasing need for treatments for atrial fibrillation in the coming years.

In many parts of Asia-Pacific, there is a growing burden of cardiovascular diseases, including AFib, driven by factors such as aging populations, urbanization, and lifestyle changes. However, awareness and access to atrial fibrillation diagnosis and treatment may be limited in some areas, particularly in rural or underserved communities. On the other hand, in less developed or rural regions of the Asia-Pacific, there may be challenges in accessing healthcare services, including atrial fibrillation screening, diagnosis and treatment. More resources, healthcare infrastructure, and healthcare provider expertise may help effective management of atrial fibrillation in these areas. Cultural beliefs and practices can also influence healthcare-seeking behaviors and adherence to treatment regimens among individuals with atrial fibrillation in the Asia-Pacific region. Customized interventions to address cultural preferences and practices are essential for improving outcomes and reducing disparities in atrial fibrillation care.

Competitive Landscape

In the market for treating atrial fibrillation, there’s a lot of competition among companies. They all want to develop the best treatments for atrial fibrillation and attract more customers. These treatments can include medicines, devices, and procedures to help manage atrial fibrillation and improve patients’ lives. Pharmaceutical companies also compete to get their products approved by regulatory agencies like the FDA in the United States or the EMA in Europe. Once approved, they work to market their treatments to doctors and hospitals so they can prescribe them to patients with atrial fibrillation. The competitive landscape in the atrial fibrillation treatment market is all about companies trying to outdo each other by developing the most effective treatments and getting them into the hands of healthcare providers and patients.

Recent Developments

  • In February 2023, Abbott got the green light from the European Union and the US FDA for its TactiFlex Ablation Catheter and Sensor Enabled products. These cool catheters are designed to treat abnormal heart rhythms, like atrial fibrillation. They have a bendy tip and can sense how much force they put on the heart. The FlexAbility Ablation Catheter and Sensor Enabled got extra approval from the US FDA, meaning it can now be used to treat patients with complicated heart issues.
  • In November 2021, Medtronic, India, invented the Arctic Front Cardiac Cryoablation Catheter System. This tool helps treat atrial fibrillation by targeting a part of the heart and stopping abnormal electrical signals. These new technologies and treatments are expected to improve healthcare for patients with heart problems, leading to better outcomes.

Atrial Fibrillation Treatment Market Players

  • Boston Scientific Corporation
  • Johnson & Johnson Med Tech
  • Pfizer
  • Bristol Myers Squibb
  • Boehringer Ingelheim
  • Bayer
  • Novartis
  • AtriCure, Inc.
  • Medtronic
  • Abbott

Atrial Fibrillation Treatment Market Segments

By Type of Therapy

  • Catheter Ablation
    • Radiofrequency Based
    • Cryoablation Based
    • HIFU (High Intensity Focused Ultrasound) Based
    • Microwave Based
    • Laser-Based
  • Maze Surgery
  • Electric Cardioversion
  • Pharmaceuticals
    • Anti-Arrhythmic Drugs
    • Anti-Coagulant Drugs
    • Other Drugs

By End User

  • Hospitals
  • Specialty Clinics
  • Other End Users

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5120

You can ask any questions, please feel free to contact us at sales@towardshealthcare.com

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Web: https://www.towardshealthcare.com

Browse our Brand-New Journal@ https://www.towardspackaging.com

Browse our Consulting Website@ https://www.precedenceresearch.com

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy